Journal
LEUKEMIA
Volume 31, Issue 8, Pages 1788-1797Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2016.373
Keywords
-
Categories
Funding
- National Institutes of Health [R01CA138738-05, PO1CA059350, PO1CA190174-01, P01 CA23766, R01CA55349, P01CA00878]
- Annual Terry Fox Run for Cancer Research (New York, NY)
Ask authors/readers for more resources
CD19-directed chimeric antigen receptor (CAR) T cells are clinically effective in a limited set of leukemia patients. However, CAR T-cell therapy thus far has been largely restricted to targeting extracellular tumor-associated antigens (TAA). Herein, we report a T-cell receptor-mimic (TCRm) CAR, termed WT1-28z, that is reactive to a peptide portion of the intracellular onco-protein Wilms Tumor 1(WT1), as it is expressed on the surface of the tumor cell in the context of HLA-A*02:01. T cells modified to express WT1-28z specifically targeted and lysed HLA-A*02:01+ WT1+ tumors and enhanced survival of mice engrafted with HLA-A*02: 01+, WT1+ leukemia or ovarian tumors. This in vivo functional validation of TCRm CAR T cells provides the proof-of-concept necessary to expand the range of TAA that can be effectively targeted for immunotherapy to include attractive intracellular targets, and may hold great potential to expand on the success of CAR T-cell therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available